Redeye comments on the subscription rate in Active Biotech's rights issue. This means underwriters who are likely short-term owners obtain 17% of the new shares.
ANNONS
Redeye comments on the subscription rate in Active Biotech's rights issue. This means underwriters who are likely short-term owners obtain 17% of the new shares.
